Loading...
•
Sep 30, 2020
Applied Therapeutics Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
Applied Therapeutics reported on their Diabetic Cardiomyopathy program, with continued enrollment in the ARISE-HF global Phase 3 registrational study. They are preparing for new rare disease clinical programs in SORD Deficiency and PMM2-CDG, planned to start in 2021, and are collaborating with the FDA to restart the ACTION-Galactosemia Kids pediatric study.
Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy.
On track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half of 2021.
Continued collaboration with FDA to restart the ACTION-Galactosemia Kids pediatric study.
Presented new data on AT-001 mechanism of action and improvement in cardiac energetics.
Applied Therapeutics
Applied Therapeutics
Forward Guidance
The company is preparing for new rare disease clinical programs in SORD Deficiency and PMM2-CDG, planned to start in 2021, and are collaborating with the FDA to restart the ACTION-Galactosemia Kids pediatric study.